Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1167

1.
2.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
3.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA.

Am J Psychiatry. 2004 Jun;161(6):985-95.

PMID:
15169686
4.

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.

Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlösser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W.

Int J Neuropsychopharmacol. 2008 Nov;11(7):985-97. doi: 10.1017/S1461145708008791. Epub 2008 May 9.

PMID:
18466670
5.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
6.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M.

J Clin Psychiatry. 2004 Apr;65(4):551-6.

PMID:
15119920
7.

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.

Tollefson GD, Sanger TM, Lu Y, Thieme ME.

Arch Gen Psychiatry. 1998 Mar;55(3):250-8. Erratum in: Arch Gen Psychiatry 1998 Nov;55(11):1052.

PMID:
9510219
8.

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.

Breier A, Hamilton SH.

Biol Psychiatry. 1999 Feb 15;45(4):403-11.

PMID:
10071708
9.

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A; HGGN Study Group.

Schizophr Res. 2006 Jan 1;81(1):1-15. Epub 2005 Oct 3.

PMID:
16202565
10.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
11.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.

Am J Psychiatry. 2002 Jun;159(6):1018-28.

PMID:
12042192
12.
13.

Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.

Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Oct;26(6):1199-202.

PMID:
12452546
14.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
15.

Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.

Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor CC, Wang J, Tran PV.

J Clin Psychopharmacol. 2001 Aug;21(4):375-81.

PMID:
11476121
16.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
17.

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM.

J Clin Psychiatry. 1997 May;58(5):205-11. Erratum in: J Clin Psychiatry 1997 Jun;58(6):275.

PMID:
9184614
18.

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.

Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine.

JAMA. 2003 Nov 26;290(20):2693-702.

PMID:
14645311
19.

Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.

Krakowski MI, Czobor P, Nolan KA.

J Clin Psychopharmacol. 2008 Oct;28(5):485-93. doi: 10.1097/JCP.0b013e3181855cd6.

PMID:
18794642
20.

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A.

Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15.

PMID:
21676992

Supplemental Content

Support Center